NCT06256055 2024-07-24
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
Phase 1 Unknown
UTC Therapeutics Inc.
Centre Hospitalier Universitaire Vaudois
Multitude Therapeutics Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Chinese PLA General Hospital
National Cancer Institute (NCI)